Researchers at the University of Southern California in Los Angeles are launching a nearly $2 million federally funded study on psychedelic-assisted therapy, combining psychedelic treatment with structured mindfulness practices in an approach designed to address some of the scientific shortcomings that have hampered the field.

The award of $1,968,826 comes from ARPA-H, the Advanced Research Projects Agency for Health, which was created in 2022 with a mandate to fund high-risk, high-reward medical research that traditional channels like the NIH tend to avoid. Psychedelic therapy fits that description squarely.

The USC study, formally called the Mindfulness-Assisted Psychedelic Therapy (MAPT) study, arrives at a pivotal moment for the field. In August 2024, the FDA rejected an application to approve MDMA-assisted therapy for PTSD, citing concerns not just about the drug's effects but about the therapy component itself: how to standardize it, how to study it rigorously, how to separate what the drug does from what the therapist does. By pairing psychedelic administration with a formalized mindfulness protocol, USC researchers appear to be building exactly the kind of structured therapeutic framework the FDA said was missing. The specific psychedelic substance the study will use has not been disclosed in the available public record.

The underlying need is hard to overstate. Roughly 30 percent of people with depression don't respond adequately to existing treatments, and no genuinely new class of psychiatric medication has reached widespread use since SSRIs in the 1990s. PTSD, particularly among veterans, remains badly undertreated. California alone has more than 1.6 million veterans, the most of any state, and Los Angeles County operates the largest county mental health department in the country.

California's political landscape adds context. In 2023, Governor Gavin Newsom vetoed a bill that would have decriminalized several psychedelics, explicitly calling for a regulated therapeutic framework to be developed before broader access. The USC grant is, in a sense, a response to that challenge.

The timing also carries some uncertainty. ARPA-H has faced scrutiny during the current administration's broader review of HHS programs, and the agency's long-term budget picture remains unsettled. Whether this grant marks a sustained federal commitment to psychedelic research or a window that could narrow will depend partly on how the study's results unfold.